Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
Esperion (NASDAQ: ESPR) is set to announce its third quarter 2022 financial results on November 1, 2022, before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Esperion (NASDAQ: ESPR) is set to announce its third quarter 2022 financial results on November 1, 2022, before U.S. markets open. Following the release, company management will host a webcast at 8:00 a.m. ET to discuss the results and business progress. Interested parties can pre-register for the webcast through their official website, where a replay will also be available approximately two hours after the call, archived for 90 days.
Esperion is focused on developing innovative cholesterol-lowering medications for patients with unmet needs.
Details
News Market Reaction – ESPR
The recorded move for ESPR in the trading session of this news was +0.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, November 1st, 2022.
Following the release, company management will host a webcast at 8:00 a.m. ET to discuss the Company’s financial results and business progress. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
Already registered? Access with your PIN here.
A live audio webcast can be accessed on the investors and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion works hard to make our medicines easy to get, easy to take and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate, and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.
Contact:
Corporate Communications
corporateteam@esperion.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.